iPS Cells & Regenerative Medicine– category –
-
BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers
BioInformant USA Overview This article provides an overview of a market research report by BioInformant, focusing on the 2026 pipeline for iPSC-derived cell therapeutics. The report analyzes the current state and future challenges, ident... -
GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea
Korea Biomedical Review South Korea Overview GC Cell's CAR-NK cell therapy, GCC2005, has received approval for compassionate use in patients with refractory T-cell lymphoma at Seoul National University Hospital (SNUH) in South Korea. Thi... -
EU-Funded PRISM-LT Project Accelerates Living Tissue Growth with Nature-Inspired 3D Bioprinting, Paving Way for Leukemia Research and Cultivated Meat Production
CORDIS - European Union European Union Overview The EU-funded PRISM-LT project has developed an innovative 3D bioprinting technology that efficiently grows living bone, fat, and muscle tissues in the laboratory. This nature-inspired plat... -
Beam Therapeutics Pursues Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Citing Positive Phase 1/2 Clinical Data
Simply Wall St USA Overview Beam Therapeutics announced updated Phase 1/2 clinical trial data for BEAM-302, its treatment for Alpha-1 Antitrypsin Deficiency (AATD), showing an acceptable safety profile and promising biomarker data indica... -
3-Year-Old’s Metastatic Liver Cancer Disappears After Two Doses of Experimental CAR T-Cell Therapy
ScienceAlert (New England Journal of Medicine) USA Overview A groundbreaking report in the New England Journal of Medicine details the complete remission of metastatic hepatoblastoma in a 3-year-old child after just two doses of an exper... -
CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 2026
MarketBeat USA Overview CRISPR Therapeutics expresses strong optimism for the continued market adoption of its approved gene-editing therapy, CASGEVY, and anticipates significant data updates from multiple key pipeline programs by the en... -
CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval
The Motley Fool USA Overview CRISPR Therapeutics reportedly aims for significant growth over the next decade by building on the commercialization of its approved sickle cell disease and transfusion-dependent beta-thalassemia therapy, CAS... -
iPS Cells & Regenerative Medicine Weekly Report September 13, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 13, 2026 (PDF) — Download Weekly Report September 13, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
Biotech M&A Heats Up: Merck KGaA Acquires Bio-Techne for $11.3B to Bolster Life Science Tools for Cell and Gene Therapy
Fintent United States Overview Fintent's September 8, 2026, report forecasts intensified M&A activity in healthcare and life sciences, highlighting Merck KGaA's $11.3 billion acquisition of Bio-Techne. This strategic move aims to str... -
Cell Therapy Startups Exceed $36 Billion in Cumulative Fundraising, Top Companies Secure Over $1 Billion Each
New Market Pitch United States Overview A report by New Market Pitch reveals that cell therapy startups have collectively surpassed $36 billion in cumulative fundraising by 2026, with leading companies each raising over $1 billion. The a...
